These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36959791)

  • 1. Erratum: Tumor response assessment on imaging following immunotherapy.
    Frontiers Production Office
    Front Oncol; 2023; 13():1175321. PubMed ID: 36959791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor response assessment on imaging following immunotherapy.
    Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
    Front Oncol; 2022; 12():982983. PubMed ID: 36387133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [
    Lopci E
    J Clin Med; 2021 Nov; 10(21):. PubMed ID: 34768681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
    Ahmed FS; Dercle L; Goldmacher GV; Yang H; Connors D; Tang Y; Karovic S; Zhao B; Carvajal RD; Robert C; Maitland ML; Oxnard GR; Schwartz LH
    Eur Radiol; 2021 Apr; 31(4):1853-1862. PubMed ID: 32995974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.
    Jia W; Gao Q; Han A; Zhu H; Yu J
    Cancer Biol Med; 2019 Nov; 16(4):655-670. PubMed ID: 31908886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of immunotherapy : Possibilities and limitations].
    Schneider H; Illert AL; Bamberg F; Eisenblätter M
    Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
    Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
    Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1.
    Castello A; Rossi S; Toschi L; Lopci E
    Front Oncol; 2020; 10():1090. PubMed ID: 32850315
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.
    Goldfarb L; Duchemann B; Chouahnia K; Zelek L; Soussan M
    EJNMMI Res; 2019 Jan; 9(1):8. PubMed ID: 30694399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRECIST: how to do it.
    Persigehl T; Lennartz S; Schwartz LH
    Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum: The landscape of immunotherapy resistance in NSCLC.
    Frontiers Production Office
    Front Oncol; 2023; 13():1187021. PubMed ID: 37081979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy, cancer and PET.
    Simó-Perdigó M; Vercher-Conejero JL; Viteri S; García-Velloso MJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(2):123-135. PubMed ID: 33674234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
    Vrankar M; Unk M
    Radiol Oncol; 2018 Oct; 52(4):365-369. PubMed ID: 30367809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
    Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of evaluating immunotherapy efficacy in solid tumors.
    Bai R; Li W; Du N; Cui J
    Chin J Cancer Res; 2019 Dec; 31(6):853-861. PubMed ID: 31949388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
    Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Huicochea Castellanos S; Pagano A; Plodkowski AJ; Girshman J; Hellmann MD; Rizvi H; Flynn J; Zheng J; Capanu M; Halpenny DF; Ginsberg MS
    Lung Cancer; 2021 Nov; 161():60-67. PubMed ID: 34536733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
    Houdek Š; Büchler T; Kindlová E
    Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.